News >

Expert Calls for a Change in the Staging of HNSCC

Angelica Welch
Published: Monday, Nov 20, 2017

Loren K. Mell, MD

Loren K. Mell, MD
The way that cancer, especially squamous cell carcinoma of the head and neck, is staged and risk stratified is inherently flawed, according to Loren K. Mell, MD.

In an interview that took place during the meeting, Mell, who is an associate professor at the University of California San Diego School of Medicine, explained his research for risk-stratifying patients with head and neck cancer.

OncLive: What are the biggest issues right now with staging for head and neck cancer?

Mell: What we are interested in knowing is, essentially, which patients are most likely to benefit from more versus less intensive therapy. There are 2 components to that. First—is this therapy more effective? Usually, the gold standard for testing that is a randomized trial. The other component is the specific individual in front of us and their characteristics.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication